Amgen Inc (AMGN) KPIs and segments
Close on Nov 18, 2026Market cap $239.98BP/E 25.7Yield 2.18%
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Amgen · năm tài chính kết thúc Calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q2 2026 ended June 30, 2026)
Nhìn nhanh KPI của Amgen: 76 chỉ số vận hành, trong đó có Total Revenues — Worldwide, Total Product Sales — Worldwide và Repatha (evolocumab, lấy từ 164 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Product sales($M)2 | 9,537 | 8,218 | 9,367 | 9,137 | 8,771 | 7,873 | 8,716 | 8,151 | 8,041 | 7,118 | 7,833 | 6,548 | |
United States($M) | 6,990 | 5,773 | 6,919 | 6,751 | 6,324 | 5,662 | 6,509 | 5,979 | 5,840 | 4,973 | 5,870 | 4,691 | |
ROW($M) | 2,547 | 2,445 | 2,448 | 2,386 | 2,447 | 2,211 | 2,207 | 2,172 | 2,201 | 2,145 | 1,963 | 1,857 | |
Other products($M)2 | 1,697 | 1,528 | 2,073 | 1,853 | 1,380 | 1,475 | 1,568 | 1,363 | 1,326 | 1,373 | 1,376 | 1,004 | |
United States($M) | 1,283 | 1,131 | 1,530 | 1,408 | 990 | 1,109 | 1,179 | 958 | 937 | 963 | 1,036 | 675 | |
ROW($M) | 414 | 397 | 543 | 445 | 390 | 366 | 389 | 405 | 389 | 410 | 340 | 329 | |
Repatha($M)2 | 953 | 876 | 794 | 696 | 656 | 606 | 567 | 532 | 517 | 417 | 406 | ||
United States($M) | 510 | 465 | 442 | 361 | 343 | 315 | 281 | 270 | 273 | 201 | 183 | ||
ROW($M) | 443 | 411 | 352 | 335 | 313 | 291 | 286 | 262 | 244 | 216 | 223 | ||
Prolia($M)2 | 759 | 727 | 1,054 | 1,139 | 1,122 | 1,099 | 1,165 | 1,045 | 1,165 | 999 | 1,107 | 986 | |
United States($M) | 478 | 461 | 707 | 806 | 745 | 720 | 775 | 683 | 770 | 657 | 746 | 673 | |
ROW($M) | 281 | 266 | 347 | 333 | 377 | 379 | 390 | 362 | 395 | 342 | 361 | 313 | |
EVENITY($M)2 | 714 | 562 | 599 | 541 | 518 | 442 | 431 | 399 | 391 | 342 | 318 | 307 | |
United States($M) | 550 | 431 | 468 | 417 | 395 | 320 | 325 | 289 | 281 | 236 | 239 | 214 | |
ROW($M) | 164 | 131 | 131 | 124 | 123 | 122 | 106 | 110 | 110 | 106 | 79 | 93 | |
ENBREL($M)2 | 580 | 320 | 532 | 580 | 604 | 510 | 1,015 | 825 | 909 | 567 | 1,015 | 1,035 | |
United States($M) | 574 | 314 | 524 | 574 | 597 | 504 | 1,008 | 817 | 902 | 561 | 1,005 | 1,026 | |
ROW($M) | 6 | 6 | 8 | 6 | 7 | 6 | 7 | 8 | 7 | 6 | 10 | 9 | |
TEPEZZA($M)2 | 576 | 490 | 457 | 560 | 505 | 381 | 460 | 488 | 479 | 424 | 448 | 0 | |
United States($M) | 520 | 424 | 409 | 518 | 466 | 365 | 456 | 482 | 478 | 419 | 441 | 0 | |
ROW($M) | 56 | 66 | 48 | 42 | 39 | 16 | 4 | 6 | 1 | 5 | 7 | 0 | |
Other revenues($M) | 517 | 400 | 499 | 420 | 408 | 276 | 370 | 352 | 347 | 329 | 363 | 355 | |
Otezla($M)2 | 491 | 431 | 625 | 585 | 618 | 437 | 624 | 564 | 544 | 394 | 629 | 567 | |
United States($M) | 431 | 352 | 511 | 473 | 512 | 343 | 514 | 460 | 432 | 293 | 526 | 462 | |
ROW($M) | 60 | 79 | 114 | 112 | 106 | 94 | 110 | 104 | 112 | 101 | 103 | 105 | |
TEZSPIRE($M)2 | 486 | 343 | 474 | 377 | 342 | 285 | 296 | 269 | 234 | 173 | 177 | 161 | |
United States($M) | 486 | 343 | 474 | 377 | 342 | 285 | 296 | 269 | 234 | 173 | 177 | 161 | |
ROW($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
BLINCYTO($M)2 | 472 | 415 | 413 | 392 | 384 | 370 | 381 | 327 | 264 | 244 | 241 | 220 | |
United States($M) | 285 | 221 | 270 | 236 | 270 | 273 | 245 | 237 | 165 | 153 | 148 | 147 | |
ROW($M) | 187 | 194 | 143 | 156 | 114 | 97 | 136 | 90 | 99 | 91 | 93 | 73 | |
Nplate($M)2 | 430 | 412 | 385 | 457 | 369 | 313 | 337 | 456 | 346 | 317 | 386 | 419 | |
United States($M) | 275 | 283 | 265 | 333 | 228 | 201 | 221 | 345 | 214 | 190 | 252 | 322 | |
ROW($M) | 155 | 129 | 120 | 124 | 141 | 112 | 116 | 111 | 132 | 127 | 134 | 97 | |
KRYSTEXXA($M)2 | 400 | 255 | 435 | 320 | 349 | 236 | 346 | 310 | 294 | 235 | 272 | 0 | |
United States($M) | 399 | 255 | 435 | 320 | 349 | 236 | 346 | 310 | 294 | 235 | 272 | 0 | |
ROW($M) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Aranesp($M)2 | 352 | 311 | 333 | 357 | 359 | 340 | 308 | 337 | 348 | 349 | 319 | 323 | |
ROW($M) | 258 | 234 | 218 | 254 | 252 | 249 | 218 | 232 | 257 | 249 | 212 | 216 | |
United States($M) | 94 | 77 | 115 | 103 | 107 | 91 | 90 | 105 | 91 | 100 | 107 | 107 | |
XGEVA($M)2 | 352 | 411 | 447 | 539 | 532 | 566 | 561 | 541 | 562 | 561 | 527 | 519 | |
United States($M) | 187 | 228 | 291 | 357 | 347 | 360 | 369 | 373 | 399 | 366 | 382 | 374 | |
ROW($M) | 165 | 183 | 156 | 182 | 185 | 206 | 192 | 168 | 163 | 195 | 145 | 145 | |
Vectibix($M)2 | 338 | 287 | 319 | 284 | 305 | 267 | 246 | 282 | 270 | 247 | 251 | 252 | |
ROW($M) | 171 | 151 | 156 | 122 | 161 | 132 | 112 | 150 | 137 | 127 | 135 | 136 | |
United States($M) | 167 | 136 | 163 | 162 | 144 | 135 | 134 | 132 | 133 | 120 | 116 | 116 | |
UPLIZNA($M)2 | 335 | 262 | 176 | 91 | |||||||||
United States($M) | 317 | 246 | 132 | 82 | |||||||||
ROW($M) | 18 | 16 | 44 | 9 | |||||||||
KYPROLIS($M)2 | 314 | 330 | 359 | 378 | 324 | 372 | 378 | 377 | 376 | 350 | 349 | ||
United States($M) | 201 | 218 | 225 | 232 | 216 | 236 | 238 | 240 | 234 | 222 | 231 | ||
ROW($M) | 113 | 112 | 134 | 146 | 108 | 136 | 140 | 137 | 142 | 128 | 118 | ||
IMDELLTRA/IMDYLLTRA($M)2 | 288 | 258 | 134 | 81 | |||||||||
United States($M) | 233 | 188 | 107 | 79 | |||||||||
ROW($M) | 55 | 70 | 27 | 2 | |||||||||
Total Revenues — Worldwide ($M)($M) | 10,054 | 8,618 | 9,866 | 9,557 | 9,179 | 8,149 | 9,086 | 8,503 | 8,388 | 7,447 | 8,196 | 6,903 | |
Total Product Sales — Worldwide ($M)($M)5 | 9,537 | 8,218 | 9,367 | 9,137 | 8,771 | 7,873 | 8,716 | 8,151 | 8,041 | 7,118 | 7,833 | 6,548 | |
Total Product Sales — United States ($M)($M)1 | 6,990 | 5,773 | 6,919 | 6,751 | 6,324 | 5,662 | 6,509 | 5,979 | 5,840 | 4,973 | 5,870 | 4,691 | |
Total Product Sales — U.S. volume growth YoY (%)(%) | 9.0% | 8.0% | 13.0% | 13.0% | 16.0% | 34.0% | 30.0% | 29.0% | |||||
Total Product Sales — Rest of World (ROW) ($M)($M)1 | 2,547 | 2,445 | 2,448 | 2,386 | 2,447 | 2,211 | 2,207 | 2,172 | 2,201 | 2,145 | 1,963 | 1,857 | |
Total Product Sales — Rest of World (ROW) volume growth YoY (%)(%) | 8.0% | 13.0% | 16.0% | 15.0% | 11.0% | 18.0% | 15.0% | 17.0% | |||||
Total Product Sales — Worldwide reported growth YoY (%)(%) | 9.0% | 4.0% | 7.0% | 12.0% | 9.0% | 11.0% | 11.0% | 24.0% | 20.0% | 22.0% | 20.0% | 5.0% | |
Total Product Sales — Worldwide volume growth YoY (%)(%) | 9.0% | 14.0% | 15.0% | 12.0% | 10.0% | 25.0% | 23.0% | ||||||
Total Product Sales — Worldwide net selling price change YoY (%)(%) | -2.0% | -6.0% | -3.0% | ||||||||||
Repatha (evolocumab — PCSK9 Inhibitor, Cardiovascular) — Worldwide product sales ($M)($M)2 | 953 | 876 | 870 | 794 | 696 | 656 | 606 | 567 | 532 | 517 | 417 | 406 | |
Repatha (evolocumab — PCSK9 Inhibitor, Cardiovascular) — Worldwide reported sales growth YoY (%)(%) | 37.0% | 34.0% | 44.0% | 40.0% | 31.0% | 27.0% | 45.0% | 40.0% | 25.0% | 33.0% | 25.0% | 31.0% | |
Repatha (evolocumab — PCSK9 Inhibitor, Cardiovascular) — Worldwide volume growth YoY (%)(%) | 35.0% | 31.0% | 36.0% | 41.0% | 41.0% | 46.0% | 44.0% | 35.0% | 43.0% | ||||
EVENITY (romosozumab-aqqg — Postmenopausal Osteoporosis) — Worldwide product sales ($M)($M)1 | 714 | 562 | 599 | 541 | 518 | 442 | 431 | 399 | 391 | 342 | 318 | 307 | |
EVENITY (romosozumab-aqqg — Postmenopausal Osteoporosis) — Worldwide reported sales growth YoY (%)(%) | 38.0% | 27.0% | 39.0% | 36.0% | 32.0% | 29.0% | 36.0% | 30.0% | 39.0% | 35.0% | 41.0% | 53.0% | |
Prolia (denosumab — Postmenopausal Osteoporosis) — Worldwide product sales ($M)($M)2 | 759 | 727 | 1,054 | 1,139 | 1,122 | 1,099 | 1,165 | 1,045 | 1,165 | 999 | 1,107 | 986 | |
Prolia (denosumab — Postmenopausal Osteoporosis) — Worldwide reported sales growth YoY (%)(%) | -32.0% | -34.0% | -10.0% | 9.0% | -4.0% | 10.0% | 5.0% | 6.0% | 13.0% | 8.0% | 12.0% | 14.0% | |
Prolia (denosumab — Postmenopausal Osteoporosis) — Worldwide net selling price change YoY (%)(%) | -12.0% | -10.0% | -8.0% | -5.0% | |||||||||
Aimovig (erenumab-aooe — Migraine Prevention, legacy standalone disclosure) — Worldwide product sales ($M)($M)3 | 78 | 94 | |||||||||||
Aimovig (erenumab-aooe — Migraine Prevention, legacy standalone disclosure) — U.S. product sales ($M)($M) | 81 | 68 | 72 | 90 | 64 | 85 | 86 | 77 | 80 | 65 | 73 | 88 | |
Aimovig (erenumab-aooe — Migraine Prevention, legacy standalone disclosure) — Rest of World (ROW) product sales ($M)($M) | 7 | 6 | 7 | 5 | 6 | 5 | 6 | 5 | 5 | 5 | 5 | 6 | |
Aimovig (erenumab-aooe — Migraine Prevention, legacy standalone disclosure) — Worldwide reported sales growth YoY (%)(%) | -32.0% | -12.0% | |||||||||||
TEPEZZA (teprotumumab-trbw — Thyroid Eye Disease) — Worldwide product sales ($M)($M)1 | 576 | 490 | 457 | 560 | 505 | 381 | 460 | 488 | 479 | 424 | 448 | 0 | |
TEPEZZA (teprotumumab-trbw — Thyroid Eye Disease) — Worldwide reported sales growth YoY (%)(%) | 14.0% | 29.0% | -1.0% | 15.0% | 5.0% | -10.0% | 3.0% | ||||||
KRYSTEXXA (pegloticase — Uncontrolled Chronic Gout) — Worldwide product sales ($M)($M)1 | 400 | 255 | 435 | 320 | 349 | 236 | 346 | 310 | 294 | 235 | 272 | 0 | |
KRYSTEXXA (pegloticase — Uncontrolled Chronic Gout) — Worldwide reported sales growth YoY (%)(%) | 15.0% | 8.0% | 26.0% | 3.0% | 19.0% | 0.0% | 27.0% | ||||||
TAVNEOS (avacopan — ANCA-Associated Vasculitis) — Worldwide product sales ($M)($M)4 | 150 | 119 | 152 | 107 | 110 | 90 | 81 | 80 | 71 | 51 | 44 | 37 | |
TAVNEOS (avacopan — ANCA-Associated Vasculitis) — U.S. product sales ($M)($M) | 143 | 114 | 142 | 101 | 103 | 77 | 76 | 74 | 61 | 45 | 42 | 32 | |
TAVNEOS (avacopan — ANCA-Associated Vasculitis) — Rest of World (ROW) product sales ($M)($M) | 7 | 5 | 10 | 6 | 7 | 13 | 5 | 6 | 10 | 6 | 2 | 5 | |
TAVNEOS (avacopan — ANCA-Associated Vasculitis) — Worldwide reported sales growth YoY (%)(%) | 36.0% | 32.0% | 88.0% | 34.0% | 55.0% | 76.0% | 84.0% | ||||||
TAVNEOS (avacopan — ANCA-Associated Vasculitis) — Worldwide volume growth YoY (%)(%) | 55.0% | 69.0% | 66.0% | ||||||||||
Ultra-Rare Products (RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL & QUINSAIR) — Worldwide product sales ($M)($M)4 | 149 | 98 | 157 | 200 | 183 | 179 | 214 | 188 | 187 | 169 | 164 | ||
Ultra-Rare Products (RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL & QUINSAIR) — U.S. product sales ($M)($M) | 144 | 96 | 144 | 195 | 175 | 171 | 205 | 180 | 175 | 166 | 162 | ||
Ultra-Rare Products (RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL & QUINSAIR) — Rest of World (ROW) product sales ($M)($M) | 5 | 2 | 13 | 5 | 8 | 8 | 9 | 8 | 12 | 3 | 2 | ||
Ultra-Rare Products (RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL & QUINSAIR) — Worldwide reported sales growth YoY (%)(%) | -19.0% | -45.0% | -27.0% | 6.0% | -2.0% | 6.0% | 30.0% | ||||||
PROCYSBI (cysteamine bitartrate — Nephropathic Cystinosis) — U.S. sales ($M)($M)1 | 71 | 47 | 59 | 62 | 55 | 57 | 61 | 57 | 54 | 49 | |||
PROCYSBI — Rest of World (ROW) sales ($M)($M) | 3 | 1 | 2 | 1 | 2 | 2 | 2 | 1 | 4 | 1 | |||
TEZSPIRE (tezepelumab-ekko — Severe Asthma) — Worldwide product sales ($M)($M)2 | 486 | 343 | 474 | 377 | 342 | 285 | 296 | 269 | 234 | 173 | 177 | 161 | |
TEZSPIRE (tezepelumab-ekko — Severe Asthma) — Worldwide reported sales growth YoY (%)(%) | 42.0% | 20.0% | 60.0% | 40.0% | 46.0% | 65.0% | 67.0% | 67.0% | 76.0% | 80.0% | |||
TEZSPIRE (tezepelumab-ekko — Severe Asthma) — Worldwide volume growth YoY (%)(%) | 32.0% | 51.0% | 48.0% | ||||||||||
Otezla (apremilast — Plaque Psoriasis & Psoriatic Arthritis) — Worldwide product sales ($M)($M)2 | 491 | 431 | 625 | 585 | 618 | 437 | 624 | 564 | 544 | 394 | 629 | 567 | |
Otezla (apremilast — Plaque Psoriasis & Psoriatic Arthritis) — Worldwide reported sales growth YoY (%)(%) | -21.0% | -1.0% | 0.0% | 4.0% | 14.0% | 11.0% | -1.0% | -1.0% | -9.0% | 1.0% | 2.0% | -10.0% | |
Otezla (apremilast — Plaque Psoriasis & Psoriatic Arthritis) — Worldwide volume growth YoY (%)(%) | -6.0% | -2.0% | 6.0% | 4.0% | 4.0% | 5.0% | 5.0% | 2.0% | 3.0% | 1.0% | |||
Enbrel (etanercept — Rheumatoid Arthritis & Psoriasis) — Worldwide product sales ($M)($M)2 | 580 | 320 | 532 | 580 | 604 | 510 | 1,015 | 825 | 909 | 567 | 1,015 | 1,035 | |
Enbrel (etanercept — Rheumatoid Arthritis & Psoriasis) — Worldwide reported sales growth YoY (%)(%) | -4.0% | -37.0% | -48.0% | -30.0% | -34.0% | -10.0% | -20.0% | -15.0% | -2.0% | -8.0% | -6.0% | ||
Enbrel (etanercept — Rheumatoid Arthritis & Psoriasis) — Worldwide net selling price change YoY (%)(%) | -22.0% | -15.0% | -35.0% | -38.0% | -19.0% | -47.0% | -12.0% | ||||||
PAVBLU (aflibercept-ayyh — Eylea Biosimilar, Retinal Diseases) — Worldwide product sales ($M)($M)2 | 287 | 280 | 258 | 213 | 130 | 99 | 31 | ||||||
PAVBLU (aflibercept-ayyh — Eylea Biosimilar, Retinal Diseases) — U.S. product sales ($M)($M) | 280 | 276 | 254 | 212 | 126 | 99 | |||||||
PAVBLU (aflibercept-ayyh — Eylea Biosimilar, Retinal Diseases) — Rest of World (ROW) product sales ($M)($M) | 7 | 4 | 4 | 1 | 4 | ||||||||
AMJEVITA / AMGEVITA (adalimumab-atto — Humira Biosimilar) — Worldwide product sales ($M)($M)3 | 155 | 173 | 174 | 154 | 133 | 136 | 294 | 166 | 133 | 168 | 160 | 152 | |
AMJEVITA / AMGEVITA (adalimumab-atto — Humira Biosimilar) — U.S. product sales ($M)($M) | 26 | 41 | 28 | 16 | 4 | 153 | 28 | -9 | 30 | 33 | 23 | ||
AMJEVITA / AMGEVITA (adalimumab-atto — Humira Biosimilar) — Rest of World (ROW) product sales ($M)($M) | 129 | 132 | 146 | 138 | 133 | 132 | 141 | 138 | 142 | 138 | 127 | 129 | |
AMJEVITA / AMGEVITA (adalimumab-atto — Humira Biosimilar) — Worldwide reported sales growth YoY (%)(%) | 17.0% | 27.0% | -41.0% | -7.0% | -19.0% | 84.0% | 9.0% | -11.0% | 2.0% | 34.0% | 30.0% | ||
WEZLANA / WEZENLA (ustekinumab-auub — Stelara Biosimilar) — Worldwide product sales ($M)($M)1 | 61 | 47 | 44 | 44 | 35 | 150 | 21 | 5 | 1 | ||||
WEZLANA / WEZENLA (ustekinumab-auub — Stelara Biosimilar) — Rest of World (ROW) product sales ($M)($M) | 61 | 43 | 44 | 44 | 35 | 27 | 21 | 5 | 1 | ||||
BLINCYTO (blinatumomab — CD19 BiTE Immuno-Oncology, ALL) — Worldwide product sales ($M)($M)1 | 472 | 415 | 413 | 392 | 384 | 370 | 381 | 327 | 264 | 244 | 241 | 220 | |
BLINCYTO (blinatumomab — CD19 BiTE Immuno-Oncology, ALL) — Worldwide reported sales growth YoY (%)(%) | 23.0% | 12.0% | 8.0% | 20.0% | 45.0% | 52.0% | 58.0% | 49.0% | 28.0% | 26.0% | 47.0% | 55.0% | |
Vectibix (panitumumab — Metastatic Colorectal Cancer) — Worldwide product sales ($M)($M)2 | 338 | 287 | 319 | 284 | 305 | 267 | 246 | 282 | 270 | 247 | 251 | 252 | |
Vectibix (panitumumab — Metastatic Colorectal Cancer) — Worldwide reported sales growth YoY (%)(%) | 11.0% | 7.0% | 30.0% | 1.0% | 13.0% | 8.0% | -2.0% | 12.0% | 9.0% | 6.0% | 5.0% | 2.0% | |
Vectibix (panitumumab — Metastatic Colorectal Cancer) — Worldwide volume growth YoY (%)(%) | 11.0% | 23.0% | -4.0% | 4.0% | |||||||||
KYPROLIS (carfilzomib — Relapsed/Refractory Multiple Myeloma) — Worldwide product sales ($M)($M)2 | 314 | 330 | 351 | 359 | 378 | 324 | 372 | 378 | 377 | 376 | 350 | 349 | |
KYPROLIS (carfilzomib — Relapsed/Refractory Multiple Myeloma) — Worldwide reported sales growth YoY (%)(%) | -17.0% | 2.0% | -6.0% | -5.0% | 0.0% | -14.0% | 6.0% | 8.0% | 9.0% | 5.0% | 8.0% | 10.0% | |
KYPROLIS (carfilzomib — Relapsed/Refractory Multiple Myeloma) — Worldwide volume growth YoY (%)(%) | 8.0% | ||||||||||||
Nplate (romiplostim — Immune Thrombocytopenia) — Worldwide product sales ($M)($M)2 | 430 | 412 | 385 | 457 | 369 | 313 | 337 | 456 | 346 | 317 | 386 | 419 | |
Nplate (romiplostim — Immune Thrombocytopenia) — Worldwide reported sales growth YoY (%)(%) | 17.0% | 32.0% | 14.0% | 0.0% | 7.0% | -1.0% | -13.0% | 9.0% | 12.0% | -12.0% | -18.0% | 45.0% | |
Nplate (romiplostim — Immune Thrombocytopenia) — Worldwide volume growth YoY (%)(%) | 13.0% | 8.0% | 9.0% | 14.0% | 43.0% | ||||||||
XGEVA (denosumab — Oncology Bone Metastases & Giant Cell Tumor) — Worldwide product sales ($M)($M)1 | 352 | 411 | 447 | 539 | 532 | 566 | 561 | 541 | 562 | 561 | 527 | 519 | |
XGEVA (denosumab — Oncology Bone Metastases & Giant Cell Tumor) — Worldwide reported sales growth YoY (%)(%) | -34.0% | -27.0% | -20.0% | 0.0% | -5.0% | 1.0% | 6.0% | 4.0% | 6.0% | 5.0% | 9.0% | 5.0% | |
LUMAKRAS / LUMYKRAS (sotorasib — KRAS G12C Non-Small Cell Lung Cancer) — Worldwide product sales ($M)($M)3 | 111 | 94 | 92 | 96 | 90 | 85 | 85 | 98 | 85 | 82 | 77 | 52 | |
LUMAKRAS / LUMYKRAS (sotorasib — KRAS G12C Non-Small Cell Lung Cancer) — U.S. product sales ($M)($M) | 62 | 49 | 47 | 57 | 52 | 55 | 53 | 53 | 55 | 53 | 51 | 48 | |
LUMAKRAS / LUMYKRAS (sotorasib — KRAS G12C Non-Small Cell Lung Cancer) — Rest of World (ROW) product sales ($M)($M) | 49 | 45 | 45 | 39 | 38 | 30 | 32 | 45 | 30 | 29 | 26 | 4 | |
LUMAKRAS / LUMYKRAS (sotorasib — KRAS G12C Non-Small Cell Lung Cancer) — Worldwide reported sales growth YoY (%)(%) | 23.0% | 11.0% | 8.0% | -2.0% | 6.0% | 4.0% | 10.0% | 88.0% | 10.0% | 11.0% | 8.0% | -31.0% | |
MVASI (bevacizumab-awwb — Avastin Oncology Biosimilar) — Worldwide product sales ($M)($M)3 | 153 | 150 | 188 | 213 | 191 | 179 | 173 | 195 | 157 | 202 | 188 | 213 | |
MVASI (bevacizumab-awwb — Avastin Oncology Biosimilar) — U.S. product sales ($M)($M) | 106 | 96 | 137 | 156 | 142 | 138 | 108 | 136 | 100 | 105 | 127 | 140 | |
MVASI (bevacizumab-awwb — Avastin Oncology Biosimilar) — Rest of World (ROW) product sales ($M)($M) | 47 | 54 | 51 | 57 | 49 | 41 | 65 | 59 | 57 | 97 | 61 | 73 | |
MVASI (bevacizumab-awwb — Avastin Oncology Biosimilar) — Worldwide reported sales growth YoY (%)(%) | -20.0% | -16.0% | 9.0% | 9.0% | 22.0% | -11.0% | -8.0% | -8.0% | -20.0% | -8.0% | 2.0% | ||
KANJINTI (trastuzumab-anns — Herceptin Biosimilar, legacy standalone disclosure) — Worldwide product sales ($M)($M)3 | 42 | 20 | |||||||||||
KANJINTI (trastuzumab-anns — Herceptin Biosimilar, legacy standalone disclosure) — U.S. product sales ($M)($M) | 31 | 7 | |||||||||||
KANJINTI (trastuzumab-anns — Herceptin Biosimilar, legacy standalone disclosure) — Rest of World (ROW) product sales ($M)($M) | 11 | 13 | |||||||||||
KANJINTI (trastuzumab-anns — Herceptin Biosimilar, legacy standalone disclosure) — Worldwide reported sales growth YoY (%)(%) | -33.0% | -72.0% | |||||||||||
Aranesp (darbepoetin alfa — Nephrology & Oncology Anemia) — Worldwide product sales ($M)($M)1 | 352 | 311 | 333 | 357 | 359 | 340 | 308 | 337 | 348 | 349 | 319 | 323 | |
Aranesp (darbepoetin alfa — Nephrology & Oncology Anemia) — Worldwide reported sales growth YoY (%)(%) | -2.0% | -9.0% | 8.0% | 6.0% | 3.0% | -3.0% | -3.0% | 4.0% | -5.0% | -2.0% | -8.0% | -10.0% | |
Neulasta (pegfilgrastim — Febrile Neutropenia) — Worldwide product sales ($M)($M) | 179 | 165 | 132 | 92 | 82 | 129 | 98 | 110 | 105 | 118 | 239 | 124 | |
Parsabiv (etelcalcetide — Secondary Hyperparathyroidism) — Worldwide product sales ($M)($M)3 | 101 | 87 | 89 | 84 | 92 | 88 | 75 | 70 | 106 | 105 | 89 | 95 | |
Parsabiv (etelcalcetide — Secondary Hyperparathyroidism) — U.S. product sales ($M)($M) | 54 | 43 | 49 | 42 | 51 | 50 | 39 | 32 | 67 | 65 | 57 | 59 | |
Parsabiv (etelcalcetide — Secondary Hyperparathyroidism) — Rest of World (ROW) product sales ($M)($M) | 47 | 44 | 40 | 42 | 41 | 38 | 36 | 38 | 39 | 40 | 32 | 36 | |
Parsabiv (etelcalcetide — Secondary Hyperparathyroidism) — Worldwide reported sales growth YoY (%)(%) | 10.0% | -1.0% | 19.0% | 20.0% | -13.0% | -16.0% | -16.0% | -26.0% | 22.0% | 15.0% | -4.0% | -5.0% | |
EPOGEN (epoetin alfa — Dialysis Anemia, legacy standalone disclosure) — Worldwide product sales ($M)($M)1 | 19 | 33 | 32 | 41 | 55 | 50 | |||||||
EPOGEN (epoetin alfa — Dialysis Anemia, legacy standalone disclosure) — Worldwide reported sales growth YoY (%)(%) | -65.0% | -34.0% | -48.0% | -32.0% | -52.0% | -63.0% | |||||||
Other Products (Segment Note 2 Aggregate) — Worldwide product sales ($M)($M)2 | 1,697 | 1,528 | 2,073 | 1,853 | 1,380 | 1,475 | 1,568 | 1,363 | 1,326 | 1,373 | 1,376 | 1,004 | |
Biosimilars Included in Other Product Sales — Worldwide ($M)($M) | 199 | 185 | 189 | 151 | 172 | 171 | 218 | 148 | 183 | 176 | 93 | 104 | |
Other Residual Products (8-K Schedule) — Worldwide ($M)($M)3 | 351 | 315 | 320 | 317 | 334 | 340 | 361 | 281 | 346 | 357 | 175 | 167 | |
Other Residual Products (8-K Schedule) — U.S. ($M)($M) | 304 | 263 | 263 | 267 | 278 | 283 | 294 | 228 | 292 | 301 | 137 | 136 | |
Other Residual Products (8-K Schedule) — Rest of World (ROW) ($M)($M) | 47 | 52 | 57 | 50 | 56 | 57 | 67 | 53 | 54 | 56 | 38 | 31 | |
Other Residual Products (8-K Schedule) — Worldwide growth YoY (%)(%) | 5.0% | -7.0% | -2.0% | 3.0% | -12.0% | -14.0% | 22.0% | 13.0% | 16.0% | 9.0% | 1.0% | ||
Accrued Sales Deductions Liability — Balance Sheet Ending Reserve ($M)1 | |||||||||||||
Operating Cash Flow — Change in Accrued Sales Incentives & Allowance ($M)($M) | 1,117 | -839 | -232 | 1,184 | 627 | 486 | 658 | 929 | -77 | -316 | 520 | 242 | |
Collaborations — AstraZeneca (TEZSPIRE) Profit Share Recorded in Cost of Sales ($M)1 | |||||||||||||
BeiGene / BeOne Oncology Collaboration — R&D Cost Recovery ($M)1 | |||||||||||||
BeiGene / BeOne Medicines — Amgen Equity Ownership Stake (%)(%) | 17.0% | 17.0% | 17.0% | 17.8% | 18.0% | 18.0% | 18.0% | ||||||
R&D Expense by Stage (10-K MD&A) — Total R&D Expense ($M)($M)1 | 1,868 | 1,719 | 2,142 | 1,900 | 1,744 | 1,486 | 1,724 | 1,450 | 1,447 | 1,343 | 1,534 | 1,079 | |
R&D Expense Excluding Software (Segment Disaggregation Note 2) ($M)($M) | 1,868 | 1,719 | 2,142 | 1,900 | 1,744 | 1,486 | 1,724 | 1,450 | 1,447 | 1,343 | |||
Non-GAAP Operating Income ($M)($M)2 | 4,612 | 3,721 | 4,006 | 4,305 | 4,293 | 3,599 | 4,033 | 4,044 | 3,873 | 3,078 | 3,660 | 3,403 | |
GAAP Operating Income ($M)($M) | 3,514 | 2,666 | 2,720 | 2,526 | 2,656 | 1,178 | 2,311 | 2,047 | 1,909 | 991 | 1,271 | 2,021 | |
Non-GAAP Operating Margin as % of Product Sales (%)(%)1 | 48.4% | 45.3% | 42.8% | 47.1% | 48.9% | 45.7% | 46.3% | 49.6% | 48.2% | 43.2% | 46.7% | 52.0% | |
GAAP Operating Margin as % of Product Sales (%)(%) | 36.8% | 32.4% | 29.0% | 27.6% | 30.3% | 15.0% | 26.5% | 25.1% | 23.7% | 13.9% | 16.2% | 30.9% | |
Non-GAAP Cost of Sales ($M)($M)2 | 1,874 | 1,603 | 1,790 | 1,662 | 1,551 | 1,420 | 1,536 | 1,454 | 1,406 | 1,340 | 1,278 | 1,137 | |
GAAP Cost of Sales ($M)($M) | 2,811 | 2,744 | 2,976 | 3,082 | 3,011 | 2,968 | 3,112 | 3,310 | 3,236 | 3,200 | 3,112 | 1,806 | |
Non-GAAP Cost of Sales as % of Product Sales (%)(%)1 | 19.6% | 19.5% | 19.1% | 18.2% | 17.7% | 18.0% | 17.6% | 17.8% | 17.5% | 18.8% | 16.3% | 17.4% | |
GAAP Cost of Sales as % of Product Sales (%)(%) | 29.5% | 33.4% | 31.8% | 33.7% | 34.3% | 37.7% | 35.7% | 40.6% | 40.2% | 45.0% | 39.7% | 27.6% | |
Non-GAAP Research & Development Expense ($M)($M)2 | 1,851 | 1,711 | 2,133 | 1,890 | 1,685 | 1,475 | 1,698 | 1,440 | 1,423 | 1,317 | 1,494 | 1,070 | |
GAAP Research & Development Expense ($M)($M) | 1,868 | 1,719 | 2,142 | 1,900 | 1,744 | 1,486 | 1,724 | 1,450 | 1,447 | 1,343 | 1,534 | 1,079 | |
Non-GAAP R&D Expense as % of Product Sales (%)(%)1 | 19.4% | 20.8% | 22.8% | 20.7% | 19.2% | 18.7% | 19.5% | 17.7% | 17.7% | 18.5% | 19.1% | 16.3% | |
GAAP R&D Expense as % of Product Sales (%)(%) | 19.6% | 20.9% | 22.9% | 20.8% | 19.9% | 18.9% | 19.8% | 17.8% | 18.0% | 18.9% | 19.6% | 16.5% | |
Non-GAAP Selling, General & Administrative Expense ($M)($M)2 | 1,717 | 1,583 | 1,937 | 1,700 | 1,650 | 1,655 | 1,819 | 1,565 | 1,686 | 1,712 | 1,764 | 1,293 | |
GAAP Selling, General & Administrative Expense ($M)($M) | 1,745 | 1,602 | 1,952 | 1,720 | 1,691 | 1,687 | 1,878 | 1,625 | 1,785 | 1,808 | 2,274 | 1,353 | |
Non-GAAP SG&A Expense as % of Product Sales (%)(%)1 | 18.0% | 19.3% | 20.7% | 18.6% | 18.8% | 21.0% | 20.9% | 19.2% | 21.0% | 24.1% | 22.5% | 19.7% | |
GAAP SG&A Expense as % of Product Sales (%)(%) | 18.3% | 19.5% | 20.8% | 18.8% | 19.3% | 21.4% | 21.5% | 19.9% | 22.2% | 25.4% | 29.0% | 20.7% | |
Non-GAAP Total Operating Expenses ($M)($M)2 | 5,442 | 4,897 | 5,860 | 5,252 | 4,886 | 4,550 | 5,053 | 4,459 | 4,515 | 4,369 | 4,536 | 3,500 | |
GAAP Total Operating Expenses ($M)($M) | 6,540 | 5,952 | 7,146 | 7,031 | 6,523 | 6,971 | 6,775 | 6,456 | 6,479 | 6,456 | 6,925 | 4,882 | |
Total Non-GAAP Operating Expense Adjustments ($M)($M) | -1,098 | -1,055 | -1,286 | -1,779 | -1,637 | -2,421 | -1,722 | -1,997 | -1,964 | -2,087 | -2,389 | -1,382 | |
Non-GAAP Net Income ($M)($M)5 | 3,423 | 2,799 | 2,875 | 3,055 | 3,258 | 2,649 | 2,879 | 3,024 | 2,691 | 2,140 | 2,543 | 2,667 | |
Non-GAAP Income Before Income Taxes ($M)($M) | 4,055 | 3,241 | 3,440 | 3,737 | 3,796 | 3,103 | 3,379 | 3,490 | 3,163 | 2,529 | 3,025 | 3,178 | |
Non-GAAP Provision for Income Taxes ($M)($M) | 632 | 442 | 565 | 682 | 538 | 454 | 500 | 466 | 472 | 389 | 482 | 511 | |
Non-GAAP Effective Tax Rate (%)(%)1 | 15.6% | 13.6% | 16.4% | 18.2% | 14.2% | 14.6% | 14.8% | 13.4% | 14.9% | 15.4% | 15.9% | 16.1% | |
GAAP Effective Tax Rate (%)(%) | 14.2% | 12.7% | 12.0% | 18.0% | 8.7% | 12.3% | 19.8% | 8.7% | 6.0% | -66.2% | 10.0% | 11.1% | |
Non-GAAP Diluted Earnings Per Share ($/sh)($)1 | 6.29 | 5.15 | 5.29 | 5.64 | 6.02 | 4.90 | 5.31 | 5.58 | 4.97 | 4.71 | 4.96 | ||
GAAP Diluted Earnings Per Share ($/sh)($) | 4.37 | 3.34 | 2.45 | 5.93 | 2.65 | 3.20 | 1.16 | 5.22 | 1.38 | 1.42 | 3.22 | ||
Non-GAAP Free Cash Flow (Operating Cash Flow Less CapEx) ($M)($M) | 3,489 | 1,477 | 961 | 4,248 | 1,911 | 980 | 4,400 | 3,314 | 2,221 | 459 | 289 | 2,512 | |
Segment Expense Disaggregation (Note 2) — Manufacturing Cost of Sales Excluding Amort & Royalty ($M)($M)5 | 2,139 | 2,180 | 2,325 | 2,508 | 2,484 | 2,528 | 2,627 | 2,852 | 2,825 | 2,814 | |||
Segment Profit Share & Royalty Expense in Cost of Sales ($M)($M) | 672 | 564 | 651 | 574 | 527 | 440 | 485 | 458 | 411 | 386 | |||
Segment Selling & Marketing Expense ($M)($M) | 1,155 | 1,134 | 1,290 | 1,097 | 1,137 | 1,066 | 1,181 | 1,117 | 1,211 | 1,204 | |||
Segment General & Administrative Expense ($M)($M) | 590 | 468 | 662 | 623 | 554 | 621 | 697 | 508 | 574 | 604 | |||
Other Segment Items (Other Operating Expenses & Non-Core Items) ($M)($M) | 314 | -87 | 745 | -1,642 | 557 | -562 | 948 | -1,661 | 445 | 520 | |||
Restructuring Charges (legacy standalone disclosure) ($M)($M) | 15 | 31 | |||||||||||
Inventories — Total Net Carrying Value ($M)($M)3 | 6,220 | 6,186 | 6,225 | 6,346 | 6,583 | 6,729 | 6,998 | 7,362 | 7,995 | 8,724 | 9,518 | 5,026 | |
Inventories — Raw Materials ($M)($M) | 1,082 | 1,048 | 915 | 955 | 885 | 841 | 818 | 788 | 884 | 928 | 993 | 849 | |
Inventories — Work in Process ($M)($M) | 3,470 | 3,426 | 3,425 | 3,555 | 3,658 | 3,961 | 4,120 | 4,339 | 4,476 | 5,270 | 5,747 | 2,992 | |
Inventories — Finished Goods ($M)($M) | 1,668 | 1,712 | 1,885 | 1,836 | 2,040 | 1,927 | 2,060 | 2,235 | 2,635 | 2,526 | 2,778 | 1,185 | |
Property, Plant & Equipment — Total Net Carrying Value ($M)($M)2 | 8,547 | 8,216 | 7,913 | 7,220 | 6,855 | 6,681 | 6,543 | 6,156 | 6,097 | 6,002 | 5,941 | 5,563 | |
Accumulated Depreciation and Amortization of PP&E ($M)($M) | 9,400 | 9,300 | 11,100 | 11,000 | 10,800 | 10,600 | 10,388 | 10,300 | 10,100 | 9,900 | 9,808 | 9,700 | |
Capital Expenditures Paid ($M)($M) | 513 | 712 | 642 | 436 | 369 | 411 | 371 | 257 | 238 | 230 | 249 | 248 | |
Goodwill — Carrying Value ($M)($M)1 | 18,668 | 18,674 | 18,680 | 18,676 | 18,674 | 18,645 | 18,637 | 18,658 | 18,616 | 18,570 | 18,629 | 15,509 | |
Goodwill Foreign Currency Translation Adjustment ($M)($M) | -6 | -6 | 4 | 2 | 29 | 8 | -21 | 16 | -2 | -10 | 9 | -8 | |
Other Intangible Assets — Total Net Carrying Value ($M)($M)7 | 20,487 | 21,379 | 22,276 | 23,139 | 24,614 | 25,724 | 27,699 | 28,920 | 30,172 | 31,372 | 32,641 | 13,150 | |
Other Intangible Assets — Total Gross Carrying Value ($M)($M) | 55,016 | 55,029 | 55,060 | 55,011 | 55,407 | 55,348 | 56,122 | 56,193 | 56,221 | 56,230 | 56,447 | 35,766 | |
Other Intangible Assets — Total Accumulated Amortization ($M)($M) | 34,529 | 33,650 | 32,784 | 31,872 | 30,793 | 29,624 | 28,423 | 27,273 | 26,049 | 24,858 | 23,806 | 22,616 | |
Finite-Lived Intangible Assets — Total Net Carrying Value ($M)($M)6 | 19,777 | 20,669 | 21,566 | 22,429 | 23,904 | 24,664 | 26,639 | 27,830 | 29,022 | 30,222 | 31,423 | 12,992 | |
Finite-Lived Intangible Assets — Total Gross Carrying Value ($M)($M) | 54,306 | 54,319 | 54,350 | 54,301 | 54,697 | 54,288 | 55,062 | 55,103 | 55,071 | 55,080 | 55,229 | 35,608 | |
Finite-Lived Intangible Assets — Total Accumulated Amortization ($M)($M) | 34,529 | 33,650 | 32,784 | 31,872 | 30,793 | 29,624 | 28,423 | 27,273 | 26,049 | 24,858 | 23,806 | 22,616 | |
Developed Product Technology Rights — Net Carrying Value ($M)($M)2 | 19,343 | 20,194 | 21,051 | 21,919 | 23,355 | 24,081 | 26,017 | 27,164 | 28,301 | 29,441 | 30,582 | 12,097 | |
Developed Product Technology Rights — Gross Carrying Value ($M)($M) | 47,793 | 47,798 | 47,805 | 47,803 | 48,201 | 47,824 | 48,611 | 48,636 | 48,621 | 48,625 | 48,631 | 29,028 | |
Developed Product Technology Rights — Accumulated Amortization ($M)($M) | 28,450 | 27,604 | 26,754 | 25,884 | 24,846 | 23,743 | 22,594 | 21,472 | 20,320 | 19,184 | 18,049 | 16,931 | |
Licensing Agreements — Net Carrying Value ($M)($M)2 | 329 | 363 | 395 | 385 | 418 | 450 | 483 | 504 | 535 | 567 | 600 | 631 | |
Licensing Agreements — Gross Carrying Value ($M)($M) | 3,902 | 3,903 | 3,917 | 3,875 | 3,875 | 3,875 | 3,875 | 3,864 | 3,864 | 3,864 | 3,865 | 3,864 | |
Licensing Agreements — Accumulated Amortization ($M)($M) | 3,573 | 3,540 | 3,522 | 3,490 | 3,457 | 3,425 | 3,392 | 3,360 | 3,329 | 3,297 | 3,265 | 3,233 | |
Acquired R&D Technology Rights — Net Carrying Value ($M)($M)2 | 105 | 112 | 120 | 125 | 131 | 133 | 139 | 147 | 152 | 159 | 166 | 168 | |
Acquired R&D Technology Rights — Gross Carrying Value ($M)($M) | 1,409 | 1,416 | 1,425 | 1,421 | 1,419 | 1,387 | 1,374 | 1,400 | 1,383 | 1,388 | 1,394 | 1,377 | |
Acquired R&D Technology Rights — Accumulated Amortization ($M)($M) | 1,304 | 1,304 | 1,305 | 1,296 | 1,288 | 1,254 | 1,235 | 1,253 | 1,231 | 1,229 | 1,228 | 1,209 | |
Marketing-Related Intangible Assets — Net Carrying Value ($M)($M)2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 34 | 55 | 75 | 96 | |
Marketing-Related Intangible Assets — Gross Carrying Value ($M)($M) | 1,202 | 1,202 | 1,203 | 1,202 | 1,202 | 1,202 | 1,202 | 1,203 | 1,203 | 1,203 | 1,339 | 1,339 | |
Marketing-Related Intangible Assets — Accumulated Amortization ($M)($M) | 1,202 | 1,202 | 1,203 | 1,202 | 1,202 | 1,202 | 1,202 | 1,188 | 1,169 | 1,148 | 1,264 | 1,243 | |
Indefinite-Lived In-Process R&D (IPR&D) Intangible Assets ($M)($M) | 710 | 710 | 710 | 710 | 710 | 1,060 | 1,060 | 1,090 | 1,150 | 1,150 | 1,218 | 158 | |
Intangible Asset Amortization Expense ($M)($M)5 | 890 | 896 | 900 | 1,100 | 1,100 | 1,200 | 1,200 | 1,200 | 1,200 | 1,200 | 1,100 | 693 | |
Estimated Future Intangible Amortization — Year 1 ($M)($M) | 3,600 | 3,600 | 3,600 | 3,600 | 3,700 | 3,700 | 4,500 | 4,500 | 4,500 | 4,500 | 4,800 | 2,700 | |
Estimated Future Intangible Amortization — Year 2 ($M)($M) | 2,800 | 2,800 | 3,500 | 3,500 | 3,700 | 3,700 | 3,900 | 3,900 | 3,900 | 3,900 | 4,500 | 2,500 | |
Estimated Future Intangible Amortization — Year 3 ($M)($M) | 2,300 | 2,300 | 2,800 | 2,800 | 2,900 | 2,800 | 3,900 | 3,900 | 3,900 | 3,900 | 3,900 | 2,100 | |
Estimated Future Intangible Amortization — Year 4 ($M)($M) | 2,200 | 2,200 | 2,300 | 2,300 | 2,300 | 2,200 | 2,900 | 2,900 | 2,900 | 2,900 | 3,900 | 2,100 | |
Estimated Future Intangible Amortization — Year 5 ($M)($M) | 2,100 | 2,100 | 2,200 | 2,200 | 2,200 | 2,100 | 2,200 | 2,200 | 2,200 | 2,200 | 2,900 | 1,100 | |
Intangible Asset Impairment Charges ($M)($M) | 0 | 0 | 0 | 400 | 0 | 800 | 30 | 61 | 0 | 68 | |||
Total Depreciation and Amortization (Cash Flow Statement) ($M)($M) | 1,112 | 1,116 | 1,132 | 1,307 | 1,341 | 1,387 | 1,397 | 1,396 | 1,400 | 1,399 | 1,380 | 895 | |
Level 3 Contingent Consideration Liabilities — Ending Fair Value ($M)($M) | 171 | 173 | 161 | 95 | 90 | 104 | 106 | 112 | 107 | 96 | 96 | 98 | |
Total Debt — Carrying Value (Current + Noncurrent) ($M)($M)3 | 57,304 | 57,323 | 54,604 | 54,587 | 56,204 | 57,381 | 60,099 | 60,398 | 62,600 | 64,000 | 64,613 | 60,500 | |
Long-Term Debt — Noncurrent Carrying Value ($M)($M) | 51,859 | 51,886 | 50,005 | 52,434 | 53,760 | 54,013 | 56,549 | 56,854 | 57,117 | 60,061 | 63,170 | 59,040 | |
Short-Term Debt & Current Portion of Long-Term Debt ($M)($M) | 5,445 | 5,437 | 4,599 | 2,153 | 2,444 | 3,368 | 3,550 | 3,544 | 5,528 | 3,959 | 1,443 | 1,428 | |
Unamortized Debt Discount and Issuance Costs ($M)($M) | 1,317 | 1,329 | 1,306 | 1,317 | 1,331 | 1,345 | 1,360 | 1,373 | 1,389 | 1,404 | 1,420 | 1,423 | |
Capital Return — Dividends Declared Per Share ($/sh)4 | |||||||||||||
Dividends Paid Per Share (legacy quarterly disclosure) ($/sh)($) | 2.13 | 2.13 | |||||||||||
Total Common Stock Dividends Declared ($M)($M) | 0 | 1,362 | 2,640 | 1,308 | 0 | 1,280 | 2,487 | 1,236 | 0 | 1,208 | 1,161 | ||
Total Cash Dividends Paid ($M)($M) | 1,362 | 1,358 | 1,283 | 1,282 | 1,280 | 1,279 | 1,205 | 1,210 | 1,209 | 1,208 | 1,140 | 1,140 | |
Share Repurchases — Cash Paid for Common Stock Repurchased ($M)1 | |||||||||||||
Share Repurchases — Remaining Board Authorization Available ($M)($M) | 6,800 | 6,800 | 6,800 | 6,800 | 6,800 | 6,800 | 6,800 | 7,000 | 7,000 | 7,000 | 7,000 | 7,000 | |
Stock-Based Compensation (SBC) — Total Pre-Tax Expense ($M)($M) | 165 | 75 | 125 | 127 | 157 | 85 | 134 | 136 | 157 | 103 | 161 | 104 | |
GAAP Effective Tax Rate (%)(%) | 14.2% | 12.7% | 18.0% | 8.7% | 12.3% | 8.7% | 6.0% | -66.2% | 11.1% | ||||
Deferred Tax Liabilities (DTL) — Total Gross DTL ($M)1 | |||||||||||||
Net Deferred Tax Liabilities Recognized on Balance Sheet ($M)($M) | 1,301 | 1,344 | 1,366 | 1,458 | 1,386 | 1,510 | 1,616 | 1,711 | 1,780 | 1,862 | 2,354 | ||
Unrecognized Tax Benefits (UTB Rollforward — IRS Transfer Pricing Dispute) — Ending Gross Balance ($M)2 | |||||||||||||
Unrecognized Tax Benefits Liability Affecting Effective Tax Rate ($M)($M) | 2,844 | 2,764 | 2,690 | 2,616 | 2,511 | 2,419 | 2,349 | 2,280 | 2,205 | 3,964 | 4,680 | 4,579 | |
UTB Additions Based on Tax Positions Related to Current Year ($M)($M) | 45 | 35 | 45 | 45 | 60 | 40 | 68 | 40 | 40 | 40 | 36 | 50 | |
U.S. Personal Consumption Expenditures: Health Care Services — SAAR ($B) | 3,790.30 | 3,699.90 | 3,667.00 | 3,614.80 | 3,529.80 | 3,464.70 | 3,417.80 | 3,358.20 | 3,288.20 | 3,244.40 | 3,159.40 | 3,079.00 | |
Income Statement — Total revenues ($M)($M)17 | 10,054 | 8,618 | 9,866 | 9,557 | 9,179 | 8,149 | 9,086 | 8,503 | 8,388 | 7,447 | 8,196 | 6,903 | |
Cost of sales ($M)($M) | 2,811 | 2,744 | 2,976 | 3,082 | 3,011 | 2,968 | 3,112 | 3,310 | 3,236 | 3,200 | 3,112 | 1,806 | |
Research and development expense ($M)($M) | 1,868 | 1,719 | 2,142 | 1,900 | 1,744 | 1,486 | 1,724 | 1,450 | 1,447 | 1,343 | 1,534 | 1,079 | |
Selling, general and administrative expense ($M)($M) | 1,745 | 1,602 | 1,952 | 1,720 | 1,691 | 1,687 | 1,878 | 1,625 | 1,785 | 1,808 | 2,274 | 1,353 | |
Restructuring charges ($M)($M) | 15 | 31 | |||||||||||
Total operating expenses ($M)($M) | 6,540 | 5,952 | 7,146 | 7,031 | 6,523 | 6,971 | 6,775 | 6,456 | 6,479 | 6,456 | 6,925 | 4,882 | |
Operating income ($M)($M) | 3,514 | 2,666 | 2,720 | 2,526 | 2,656 | 1,178 | 2,311 | 2,047 | 1,909 | 991 | 1,271 | 2,021 | |
Interest expense, net ($M)($M) | 673 | 657 | 653 | 685 | 694 | 723 | 747 | 776 | 808 | 824 | 821 | 759 | |
Interest and other income, net ($M)($M) | 125 | 101 | 97 | 99 | 86 | 126 | 116 | 126 | 115 | 153 | |||
Other nonoperating income (expense) ($M)($M) | -73 | 75 | -553 | 2,080 | -394 | 1,518 | -782 | 1,830 | -307 | -235 | 402 | 685 | |
Income before income taxes ($M)($M) | 2,768 | 2,084 | 1,514 | 3,921 | 1,568 | 1,973 | 782 | 3,101 | 794 | -68 | 852 | 1,947 | |
Provision for income taxes ($M)($M) | 393 | 265 | 181 | 705 | 136 | 243 | 155 | 271 | 48 | 45 | 85 | 217 | |
Net income ($M)($M) | 2,375 | 1,819 | 1,333 | 3,216 | 1,432 | 1,730 | 627 | 2,830 | 746 | -113 | 767 | 1,730 | |
Earnings per share — Basic ($/sh)($) | 4.40 | 3.37 | 5.98 | 2.66 | 3.22 | 5.27 | 1.39 | -0.21 | 3.23 | ||||
Earnings per share — Diluted ($/sh)($) | 4.37 | 3.34 | 5.93 | 2.65 | 3.20 | 5.22 | 1.38 | -0.21 | 3.22 | ||||
Weighted-average basic shares (M)(M) | 540 | 540 | 538 | 538 | 538 | 537 | 537 | 536 | 535 | ||||
Weighted-average diluted shares (M)(M) | 544 | 544 | 542 | 541 | 541 | 542 | 541 | 536 | 538 | ||||
Dividends declared per share ($/sh)($) | 0 | 2.52 | 2.52 | 2.38 | 2.38 | 2.38 | 2.25 | 2.25 | 2.25 | 2.25 | 2.13 | 2.13 | |
Balance Sheet — Total assets ($M)($M)22 | 95,639 | 92,504 | 90,586 | 90,141 | 87,897 | 89,367 | 91,839 | 90,883 | 90,907 | 92,980 | 97,154 | 90,534 | |
Cash and cash equivalents ($M)($M) | 13,989 | 12,038 | 9,129 | 9,445 | 8,028 | 8,810 | 11,973 | 9,011 | 9,301 | 9,708 | 10,944 | 34,741 | |
Marketable securities ($M)($M) | 0 | 0 | |||||||||||
Trade receivables, net ($M)($M) | 10,227 | 9,138 | 9,570 | 8,490 | 8,701 | 8,132 | 6,782 | 7,317 | 6,934 | 6,776 | 7,268 | 6,145 | |
Inventories ($M)($M) | 6,220 | 6,186 | 6,225 | 6,346 | 6,583 | 6,729 | 6,998 | 7,362 | 7,995 | 8,724 | 9,518 | 5,026 | |
Other current assets ($M)($M) | 4,525 | 4,113 | 4,133 | 3,604 | 3,422 | 3,258 | 3,277 | 3,076 | 2,976 | 2,821 | 2,602 | 2,565 | |
Total current assets ($M)($M) | 34,961 | 31,475 | 29,057 | 27,885 | 26,734 | 26,929 | 29,030 | 26,766 | 27,206 | 28,029 | 30,332 | 48,477 | |
Accumulated depreciation ($M)($M) | -9,400 | -9,300 | -11,100 | -11,000 | -10,800 | -10,600 | -10,388 | -10,300 | -10,100 | -9,900 | -9,808 | -9,700 | |
Property, plant and equipment, net ($M)($M) | 8,547 | 8,216 | 7,913 | 7,220 | 6,855 | 6,681 | 6,543 | 6,156 | 6,097 | 6,002 | 5,941 | 5,563 | |
Intangible assets, net ($M)($M) | 20,487 | 21,379 | 22,276 | 23,139 | 24,614 | 25,724 | 27,699 | 28,920 | 30,172 | 31,372 | 32,641 | 13,150 | |
Goodwill ($M)($M) | 18,668 | 18,674 | 18,680 | 18,676 | 18,674 | 18,645 | 18,637 | 18,658 | 18,616 | 18,570 | 18,629 | 15,509 | |
Other noncurrent assets ($M)($M) | 12,976 | 12,760 | 12,660 | 13,221 | 11,020 | 11,388 | 9,930 | 10,383 | 8,816 | 9,007 | 9,611 | 7,835 | |
Accounts payable ($M)($M) | 2,865 | 2,935 | 2,367 | 2,838 | 3,010 | 2,406 | 1,908 | 2,147 | 2,267 | 1,628 | 1,590 | 1,358 | |
Accrued liabilities ($M)($M) | 17,192 | 16,583 | 18,523 | 16,800 | 15,022 | 17,234 | 17,641 | 14,621 | 13,722 | 14,127 | 15,359 | 14,168 | |
Total current liabilities ($M)($M) | 25,502 | 24,955 | 25,489 | 21,791 | 20,476 | 23,008 | 23,099 | 20,312 | 21,517 | 19,714 | 18,392 | 16,954 | |
Long-term debt ($M)($M) | 51,859 | 51,886 | 50,005 | 52,434 | 53,760 | 54,013 | 56,549 | 56,854 | 57,117 | 60,061 | 63,170 | 59,040 | |
Deferred tax liabilities ($M)($M) | 1,301 | 1,344 | 1,366 | 1,458 | 1,386 | 1,510 | 1,616 | 1,711 | 1,780 | 1,862 | 2,354 | ||
Other noncurrent liabilities ($M)($M) | 2,445 | 2,365 | 2,378 | 2,223 | 2,336 | 2,210 | 2,349 | 2,199 | 2,363 | 2,357 | 2,326 | 2,305 | |
Retained earnings (accumulated deficit) ($M)($M) | -22,275 | -24,650 | -25,107 | -23,800 | -25,708 | -27,140 | -27,590 | -25,530 | -27,124 | -27,870 | -26,549 | -24,971 | |
Accumulated other comprehensive income (loss) ($M)($M) | -119 | -190 | -258 | -422 | -544 | -231 | -66 | -336 | -155 | -190 | -289 | -126 | |
Total stockholders' equity ($M)($M) | 11,688 | 9,190 | 8,658 | 9,619 | 7,428 | 6,207 | 5,877 | 7,527 | 5,925 | 5,022 | 6,232 | 7,656 | |
Total liabilities and stockholders' equity ($M)($M) | 95,639 | 92,504 | 90,586 | 90,141 | 87,897 | 89,367 | 91,839 | 90,883 | 90,907 | 92,980 | 97,154 | 90,534 | |
Common shares outstanding at period end (M)(M) | 541 | 540 | 539 | 539 | 538 | 538 | 537 | 538 | 537 | 536 | 535 | 535 | |
Cash Flow Statement — Operating cash flow ($M)($M)12 | 4,002 | 2,189 | 1,603 | 4,684 | 2,280 | 1,391 | 4,771 | 3,571 | 2,459 | 689 | 538 | 2,760 | |
Depreciation and amortization ($M)($M) | 222 | 1,116 | 1,132 | 232 | 220 | 1,387 | 1,397 | 198 | 202 | 1,399 | 1,380 | 895 | |
Stock-based compensation ($M)($M) | 165 | 75 | 125 | 127 | 157 | 85 | 134 | 136 | 157 | 103 | 161 | 104 | |
Deferred income taxes ($M)($M) | -291 | -176 | 2 | -30 | -422 | -250 | -344 | -110 | -383 | -401 | -565 | -447 | |
Change in trade receivables ($M)($M) | -1,093 | 413 | -1,075 | 222 | -515 | -1,308 | 473 | -342 | -176 | 486 | -433 | -342 | |
Change in inventories ($M)($M) | -31 | 18 | 119 | 240 | 239 | 288 | 323 | 681 | 722 | 806 | 573 | -54 | |
Change in accounts payable ($M)($M) | -70 | 571 | -484 | -174 | 589 | 497 | -232 | -122 | 643 | 23 | -187 | 156 | |
Capital expenditures ($M)($M) | 513 | 712 | 642 | 436 | 369 | 411 | 371 | 257 | 238 | 230 | 249 | 248 | |
Net cash used in investing activities ($M)($M) | -569 | -716 | -693 | -414 | -389 | -447 | -402 | -210 | -217 | -217 | -27,089 | -262 | |
Proceeds from issuance of long-term debt ($M)($M) | 0 | 3,964 | 0 | 0 | 0 | 0 | 0 | 0 | 3,996 | 1 | |||
Repayments of long-term debt ($M)($M) | -0 | 833 | -0 | 1,500 | 1,000 | 2,500 | -0 | 2,200 | 1,400 | -0 | -0 | 750 | |
Cash dividends paid ($M)($M) | 1,362 | 1,358 | 1,283 | 1,282 | 1,280 | 1,279 | 1,205 | 1,210 | 1,209 | 1,208 | 1,140 | 1,140 | |
Net cash used in financing activities ($M)($M) | -1,482 | 1,436 | -1,226 | -2,853 | -2,673 | -4,107 | -1,407 | -3,651 | -2,649 | -1,708 | 2,754 | -2,005 | |
26 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Fiscal calendar: Amgen Inc. operates on a calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q1 2026 ended March 31, 2026; Q2 2026 ended June 30, 2026). Amgen operates as a single global human therapeutics operating segment (Note 2), so commercial performance is tracked across 4 Therapeutic Franchises (General Medicine, Rare Disease, Inflammation, Oncology & Established Products) and 35+ commercialized brands disaggregated across United States (U.S.), Rest of World (ROW), and Worldwide (WW) net product sales.
- Core commercial & R&D KPIs (Groups 1–6) cover: (1) Consolidated Revenues ($10,054M in Q2 2026 / $36,751M in FY25) and Total Product Sales ($9,567M in Q2 2026 / $35,147M in FY25 across U.S. $6,767M and ROW $2,800M in Q2 2026; U.S. volume +9% and ROW volume +8% YoY in Q2 2026) and General Medicine (Repatha $953M, EVENITY $714M, Prolia $759M in Q2 2026); (2) Rare Disease Franchise acquired via Horizon Therapeutics & ChemoCentryx (TEPEZZA $576M, KRYSTEXXA $400M, UPLIZNA $335M, TAVNEOS $150M, Ultra-Rare Products $168M in Q2 2026 including RAVICTI & PROCYSBI U.S./ROW breakdown); (3) Inflammation & Biosimilars (TEZSPIRE $486M, Otezla $491M, Enbrel $580M, PAVBLU $287M, AMJEVITA $155M, WEZLANA $14M in Q2 2026); (4) Oncology & Established Products (BLINCYTO $472M, IMDELLTRA $288M, Vectibix $338M, KYPROLIS $314M, Nplate $430M, XGEVA $352M, LUMAKRAS $111M, MVASI $153M, Aranesp $352M, Neulasta $92M, Parsabiv $90M in Q2 2026, plus Biosimilars in Other Products $372M in Q2 2026 / $1,422M in FY25); (5) Gross-to-Net (GTN) Sales Deductions Rollforward ($40,664M provisions / 54% of gross product sales and $6,661M ending reserve in FY25 across Rebates $30,275M, Chargebacks $9,081M & Other $1,308M), Top 3 U.S. Wholesalers (McKesson $20,986M / 27%, Cencora $19,708M / 25%, Cardinal Health $13,075M / 17% — combined 69% of worldwide gross revenues and 75% of net trade receivables in FY25), and Collaboration Profit Sharing (AstraZeneca TEZSPIRE, UCB EVENITY, Kyowa Kirin, BeiGene/BeOne); and (6) R&D by Clinical Stage ($7,232M total in FY25: Research & Early Pipeline $2,021M, Later-Stage Clinical Phase 2/3 $3,769M, Marketed Product Support $1,442M) and 8-K GAAP vs. Non-GAAP Reconciliations (48.4% Non-GAAP Operating Margin, $6.29 Non-GAAP Diluted EPS, $3,505M Free Cash Flow in Q2 2026).
- Extended operational & ESG KPIs (Groups 7–11) cover: (7) Note 2 Segment Expenses (Manufacturing COGS $1,089M, Profit Share & Royalty COGS $817M, R&D Ex-Software $1,796M, Selling & Marketing $1,226M, G&A $539M in Q2 2026), Inventories by stage ($5,638M net at FY25), and Net PP&E by asset class & geography ($6,568M net at FY25, including $1,334M in Puerto Rico); (8) Goodwill ($18,625M at Q2 2026), Finite-Lived Intangible Assets ($22,256M net at Q2 2026 across Developed Technology, Licensing, Acquired R&D & Marketing-Related), Indefinite-Lived IPR&D ($1,225M), 5-year estimated amortization schedule, and Level 3 Contingent Consideration Rollforward; (9) Debt & 5-year maturity schedule ($53,015M total debt at Q2 2026), Operating Leases ($601M ROU assets / $617M lease liabilities at FY25), Capital Return ($2.52/sh dividend in Q2 2026), and SBC by award type; (10) Income Taxes, DTA/DTL breakdown & Unrecognized Tax Benefits Rollforward ($10,169M gross UTB balance & $5,088M accrued UTB interest/penalties at FY25 related to the IRS Puerto Rico transfer pricing dispute); and (11) Global Workforce (28,200 staff in FY25), CEO Pay Ratio (153:1 / $158,361 median employee in FY25), Form 11-K U.S. Plan ($8,963.48M net assets) & Puerto Rico Plan ($464.56M net assets at FY25), Patient Access ($3.2B U.S. Safety Net Foundation & $232M LMIC donations in FY25), Workplace Safety (0.21 staff TRIR in FY25), and Scope 1, 2 & 3 GHG Emissions, Energy, Water & Waste.
- No parent-only standalone financial statements exist under U.S. GAAP (Form 10-K omits Schedule I), so no Consolidated − Standalone subtraction is performed. All values are strictly as published (with verbatim quotes on hover for text-extracted metrics; bound disclosures are excluded from table cells). The only arithmetic shown in table cells is period splitting (Q4 = full year − 9M; Q2 = 6M − Q1; Q3 = 9M − 6M), displayed in italic with the formula.
Không hiện vì thiếu các kỳ gần đây (3)
- Human Capital, CEO Pay Ratio (DEF 14A), Form 11-K U.S. & Puerto Rico Retirement Plans, Patient Access & Environmental Sustainability › Workplace Safety — Staff Total Recordable Incident Rate (TRIR per 200,000 hours) › Environmental Notices of Violation (NOVs)
- Industry & Macro Healthcare Benchmarks (FRED) & Core Financial Statements (DB) › Income Statement — Total revenues ($M) › Gross profit ($M)
- Industry & Macro Healthcare Benchmarks (FRED) & Core Financial Statements (DB) › Balance Sheet — Total assets ($M) › Current portion of long-term debt ($M)
Dữ liệu cập nhật 2026-10-28.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Consolidated Geographic Revenues, Volume/Price Drivers & General Medicine Franchise (Repatha, EVENITY, Prolia)
- Total Revenues — Worldwide ($M) ($M)46 kỳ
- Total Product Sales — Worldwide ($M) ($M)46 kỳ
- Repatha (evolocumab — PCSK9 Inhibitor, Cardiovascular) — Worldwide product sales ($M) ($M)36 kỳ
- EVENITY (romosozumab-aqqg — Postmenopausal Osteoporosis) — Worldwide product sales ($M) ($M)30 kỳ
- Prolia (denosumab — Postmenopausal Osteoporosis) — Worldwide product sales ($M) ($M)38 kỳ
- Aimovig (erenumab-aooe — Migraine Prevention, legacy standalone disclosure) — Worldwide product sales ($M) ($M)23 kỳ
Rare Disease Franchise (TEPEZZA, KRYSTEXXA, UPLIZNA, TAVNEOS & Ultra-Rare Products)
- TEPEZZA (teprotumumab-trbw — Thyroid Eye Disease) — Worldwide product sales ($M) ($M)14 kỳ
- KRYSTEXXA (pegloticase — Uncontrolled Chronic Gout) — Worldwide product sales ($M) ($M)14 kỳ
- UPLIZNA (inebilizumab-cdon — NMOSD & IgG4-Related Disease) — Worldwide product sales ($M) ($M)11 kỳ
- TAVNEOS (avacopan — ANCA-Associated Vasculitis) — Worldwide product sales ($M) ($M)15 kỳ
- Ultra-Rare Products (RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL & QUINSAIR) — Worldwide product sales ($M) ($M)11 kỳ
Inflammation & Immunology Biosimilars Franchise (TEZSPIRE, Otezla, Enbrel, PAVBLU, AMJEVITA, WEZLANA)
- TEZSPIRE (tezepelumab-ekko — Severe Asthma) — Worldwide product sales ($M) ($M)18 kỳ
- Otezla (apremilast — Plaque Psoriasis & Psoriatic Arthritis) — Worldwide product sales ($M) ($M)30 kỳ
- Enbrel (etanercept — Rheumatoid Arthritis & Psoriasis) — Worldwide product sales ($M) ($M)38 kỳ
- PAVBLU (aflibercept-ayyh — Eylea Biosimilar, Retinal Diseases) — Worldwide product sales ($M) ($M)7 kỳ
- AMJEVITA / AMGEVITA (adalimumab-atto — Humira Biosimilar) — Worldwide product sales ($M) ($M)31 kỳ
- WEZLANA / WEZENLA (ustekinumab-auub — Stelara Biosimilar) — Worldwide product sales ($M) ($M)9 kỳ
Oncology & Hematology Franchise (BLINCYTO, IMDELLTRA, Vectibix, KYPROLIS, Nplate, XGEVA, LUMAKRAS) & Established Products
- BLINCYTO (blinatumomab — CD19 BiTE Immuno-Oncology, ALL) — Worldwide product sales ($M) ($M)36 kỳ
- IMDELLTRA / IMDYLLTRA (tarlatamab-dlle — DLL3 BiTE, Small Cell Lung Cancer) — Worldwide product sales ($M) ($M)9 kỳ
- Vectibix (panitumumab — Metastatic Colorectal Cancer) — Worldwide product sales ($M) ($M)36 kỳ
- KYPROLIS (carfilzomib — Relapsed/Refractory Multiple Myeloma) — Worldwide product sales ($M) ($M)36 kỳ
- Nplate (romiplostim — Immune Thrombocytopenia) — Worldwide product sales ($M) ($M)36 kỳ
- XGEVA (denosumab — Oncology Bone Metastases & Giant Cell Tumor) — Worldwide product sales ($M) ($M)38 kỳ
- LUMAKRAS / LUMYKRAS (sotorasib — KRAS G12C Non-Small Cell Lung Cancer) — Worldwide product sales ($M) ($M)21 kỳ
- MVASI (bevacizumab-awwb — Avastin Oncology Biosimilar) — Worldwide product sales ($M) ($M)28 kỳ
- KANJINTI (trastuzumab-anns — Herceptin Biosimilar, legacy standalone disclosure) — Worldwide product sales ($M) ($M)21 kỳ
- Aranesp (darbepoetin alfa — Nephrology & Oncology Anemia) — Worldwide product sales ($M) ($M)38 kỳ
- Neulasta (pegfilgrastim — Febrile Neutropenia) — Worldwide product sales ($M) ($M)38 kỳ
- Parsabiv (etelcalcetide — Secondary Hyperparathyroidism) — Worldwide product sales ($M) ($M)36 kỳ
- EPOGEN (epoetin alfa — Dialysis Anemia, legacy standalone disclosure) — Worldwide product sales ($M) ($M)32 kỳ
- NEUPOGEN (filgrastim — Neutropenia, legacy standalone disclosure) — Worldwide product sales ($M) ($M)22 kỳ
- Sensipar / Mimpara (cinacalcet — Secondary Hyperparathyroidism, legacy standalone disclosure) — Worldwide product sales ($M) ($M)24 kỳ
- Other Products (Segment Note 2 Aggregate) — Worldwide product sales ($M) ($M)38 kỳ
Gross-to-Net (GTN) Deductions Rollforward, Wholesaler Concentration & Strategic Collaborations
- Accrued Sales Deductions Liability — Balance Sheet Ending Reserve ($M) ($M)13 kỳ
- Gross-to-Net Sales Deductions — Annual Provisions Charged Against Gross Product Sales ($M) ($M)12 kỳ
- Gross-to-Net Sales Deductions — Annual Cash Payments & Credit Utilizations ($M) ($M)8 kỳ
- Major Customer Concentration — McKesson Corporation Gross Product Sales ($M) ($M)11 kỳ
- Collaborations — AstraZeneca (TEZSPIRE) Profit Share Recorded in Cost of Sales ($M) ($M)4 kỳ
R&D Expense by Clinical Stage (10-K MD&A) & GAAP vs. Non-GAAP Operating Reconciliations (8-K)
- R&D Expense by Stage (10-K MD&A) — Total R&D Expense ($M) ($M)46 kỳ
- Non-GAAP Operating Income ($M) ($M)36 kỳ
- Non-GAAP Cost of Sales ($M) ($M)36 kỳ
- Non-GAAP Research & Development Expense ($M) ($M)36 kỳ
- Non-GAAP Selling, General & Administrative Expense ($M) ($M)36 kỳ
- Non-GAAP Total Operating Expenses ($M) ($M)36 kỳ
- Non-GAAP Net Income ($M) ($M)36 kỳ
Segment Expense Disaggregation (Note 2), Inventories by Stage & PP&E by Asset Class & Geography (Puerto Rico Hub)
Goodwill, Intangible Assets by Class, 5-Year Amortization Schedule & Level 3 Contingent Consideration Rollforward
Debt & 5-Year Maturity Schedule, Operating Leases (ASC 842), Capital Return & Stock-Based Compensation
Income Taxes by Jurisdiction, Effective Tax Rate Drivers, DTA/DTL Breakdown & Unrecognized Tax Benefits (UTB) Rollforward
- Pre-Tax Income by Jurisdiction — Foreign Operations ($M) ($M)11 kỳ
- GAAP Effective Tax Rate (%) (%)35 kỳ
- Deferred Tax Assets (DTA) — Total Gross DTA ($M) ($M)11 kỳ
- Deferred Tax Liabilities (DTL) — Total Gross DTL ($M) ($M)11 kỳ
- Unrecognized Tax Benefits (UTB Rollforward — IRS Transfer Pricing Dispute) — Ending Gross Balance ($M) ($M)11 kỳ
Human Capital, CEO Pay Ratio (DEF 14A), Form 11-K U.S. & Puerto Rico Retirement Plans, Patient Access & Environmental Sustainability
- Human Capital — Total Global Staff Members (employees)11 kỳ
- Executive Compensation (DEF 14A) — CEO Pay Ratio (x:1) (×)7 kỳ
- Defined Contribution Employee Benefit Plans — Total Company Expense (10-K) ($M) ($M)10 kỳ
- Patient Access — Amgen Safety Net Foundation Free Medicine Provided in U.S. (Wholesale Acquisition Cost) ($B)4 kỳ
- Workplace Safety — Staff Total Recordable Incident Rate (TRIR per 200,000 hours) (×)7 kỳ
- Energy Consumption — Total Energy for On-Site Facilities (1,000 GJ)7 kỳ
- Climate & Carbon — Net Scope 1 & 2 Market-Based GHG Emissions (1,000 MT CO2e) (M)5 kỳ
- Water Stewardship — Total Water Withdrawal (1,000 m3)7 kỳ
- Waste Management — Total Routine Operational Waste Generated (1,000 metric tons) (M)7 kỳ
Industry & Macro Healthcare Benchmarks (FRED) & Core Financial Statements (DB)
- PPI: Pharmaceutical Preparation Manufacturing (Index Dec 1981=100) (×)129 kỳ
- CPI: Medical Care Commodities in U.S. City Average (Index 1982-84=100) (×)128 kỳ
- U.S. Retail Sales: Pharmacies and Drug Stores — Seasonally Adjusted ($M) ($M)128 kỳ
- U.S. Personal Consumption Expenditures: Health Care Services — SAAR ($B)42 kỳ
- Income Statement — Total revenues ($M) ($M)61 kỳ
- Balance Sheet — Total assets ($M) ($M)63 kỳ
- Cash Flow Statement — Operating cash flow ($M) ($M)60 kỳ
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Amgen
- Form 10-Q (filed 2026-08-05) ↗
- Form 10-K (filed 2026-02-13) ↗
- Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗
- Form 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗
- Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗
- Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗
- Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗
- Amgen Sustainability Report (amgen-2025-sustainability-highlights-report.pdf) ↗
- Amgen Sustainability Report (2025_summary_of_data.pdf) ↗
- Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗
- Proxy Statement (DEF 14A) (d13946ddef14a.htm, filed 2026-04-07) ↗
- FRED (PCU325412325412) ↗
See a number that looks wrong?